Helix BioPharma Corp. has significantly bolstered its leadership team by recruiting three prominent oncology and scientific experts, positioning the company to advance its innovative cancer therapy research and development strategies.
The new appointments include Dr. Thomas Mehrling as Chief Medical Officer, Dr. Jonathan Davis as Director of ADC Discovery, and Dr. Davide Guggi as Chief Technology Officer. Each brings extensive experience in oncology, drug development, and therapeutic innovation.
Dr. Mehrling, with 20 years of experience in oncology, will lead clinical development strategy, focusing initially on the Tumor Defence Breaker™ L-DOS47, a first-in-class antibody-enzyme conjugate targeting Non-Small Cell Lung Cancer. His previous roles at pharmaceutical giants like Takeda and Roche demonstrate a track record of introducing groundbreaking cancer treatments.
Dr. Davis joins the team as a leading expert in therapeutic antibodies, specializing in advancing Antibody-Drug Conjugate (ADC) discovery. His expertise will be crucial in developing bi-specific ADCs and radionuclide drug conjugates targeting specific cancer markers like Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CECAM6).
Dr. Guggi brings comprehensive Chemistry, Manufacturing, and Controls (CMC) expertise, having collaborated with over 20 global biotech firms. His role will focus on ensuring seamless clinical development and optimizing the scalability of Helix's compound therapies.
These strategic appointments underscore Helix BioPharma's commitment to assembling a world-class team capable of pushing the boundaries of cancer treatment. By combining deep scientific expertise with innovative research approaches, the company aims to develop next-generation therapies that offer meaningful improvements in treating challenging solid tumors.
